PILERI, STEFANO
 Distribuzione geografica
Continente #
NA - Nord America 17.134
EU - Europa 12.123
AS - Asia 4.288
AF - Africa 691
SA - Sud America 29
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 13
Totale 34.300
Nazione #
US - Stati Uniti d'America 17.076
GB - Regno Unito 4.086
CN - Cina 1.928
DE - Germania 1.696
SE - Svezia 1.584
VN - Vietnam 1.304
IT - Italia 1.258
UA - Ucraina 1.006
IN - India 737
FR - Francia 548
RU - Federazione Russa 524
IE - Irlanda 484
ZA - Sudafrica 346
EE - Estonia 299
CH - Svizzera 220
TG - Togo 137
CI - Costa d'Avorio 78
SC - Seychelles 73
HR - Croazia 71
FI - Finlandia 70
JO - Giordania 68
BG - Bulgaria 61
GR - Grecia 60
BE - Belgio 56
IR - Iran 55
CA - Canada 53
JP - Giappone 51
NG - Nigeria 43
LB - Libano 33
NL - Olanda 23
TR - Turchia 19
BR - Brasile 17
EU - Europa 17
SG - Singapore 16
HK - Hong Kong 13
UZ - Uzbekistan 12
KR - Corea 11
PL - Polonia 11
ES - Italia 10
PT - Portogallo 10
RO - Romania 9
AT - Austria 8
AU - Australia 8
CL - Cile 7
CZ - Repubblica Ceca 7
IQ - Iraq 6
A2 - ???statistics.table.value.countryCode.A2??? 5
MY - Malesia 5
NZ - Nuova Zelanda 5
PH - Filippine 5
ET - Etiopia 4
IL - Israele 4
LU - Lussemburgo 4
PE - Perù 4
PK - Pakistan 4
SK - Slovacchia (Repubblica Slovacca) 4
TN - Tunisia 4
BD - Bangladesh 3
DK - Danimarca 3
HU - Ungheria 3
MX - Messico 3
AL - Albania 2
CU - Cuba 2
EG - Egitto 2
ID - Indonesia 2
KW - Kuwait 2
NO - Norvegia 2
SA - Arabia Saudita 2
UG - Uganda 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
DZ - Algeria 1
GE - Georgia 1
GH - Ghana 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
MK - Macedonia 1
MT - Malta 1
RS - Serbia 1
TH - Thailandia 1
TW - Taiwan 1
Totale 34.300
Città #
Southend 3.699
Fairfield 2.741
Ashburn 1.407
Woodbridge 1.379
Chandler 1.266
Houston 1.248
Wilmington 1.201
Seattle 1.190
Cambridge 981
Princeton 882
Ann Arbor 813
Dong Ket 694
Jacksonville 638
Dublin 484
Nanjing 403
Westminster 382
Padova 371
Berlin 226
Saint Petersburg 204
Bern 192
Jinan 182
Bologna 181
Shenyang 162
Mülheim 146
Nanchang 143
San Diego 141
Lomé 137
Hebei 133
New York 120
Changsha 113
Bremen 112
Beijing 98
Tianjin 93
Boardman 86
Milan 86
Jiaxing 85
Abidjan 78
Medford 70
Mahé 69
Amman 68
Helsinki 67
Sofia 61
Dearborn 60
Norwalk 55
Hangzhou 54
Redwood City 54
Zhengzhou 54
Ningbo 53
Brussels 52
Turin 52
Falls Church 50
Olalla 49
San Venanzo 49
Haikou 47
Taizhou 46
Tokyo 44
Abeokuta 42
Des Moines 40
Redmond 40
Verona 40
Guangzhou 37
Taiyuan 34
Lanzhou 33
Toronto 32
Bühl 25
Fremont 23
Kunming 22
Paris 22
Florence 21
Fuzhou 21
Pune 20
Frankfurt Am Main 19
London 19
Leawood 18
Los Angeles 17
Rome 17
Hefei 16
Istanbul 16
Moscow 16
Chicago 15
Frankfurt am Main 15
Andover 14
Lausanne 14
Monmouth Junction 13
San Francisco 13
Zanjan 13
Buffalo 12
Ardabil 10
Phoenix 10
São Paulo 10
Wayne 10
Plauen 9
Rijeka 9
Athens 8
Kuban 8
Sacramento 8
Salsomaggiore Terme 8
Ulan-ude 8
Amsterdam 7
Chiswick 7
Totale 24.362
Nome #
Biology and treatment of follicular lymphoma. 190
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 187
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 181
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 177
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 174
ANALYSIS OF THE CODING GENOME OF SPLENIC MARGINAL ZONE LYMPHOMA REVEALS MUTATIONAL ACTIVATION OF NOTCH2 AND OTHER PATHWAYS REGULATING MARGINAL ZONE DIFFERENTIATION 172
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 171
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target 171
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 165
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 158
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply 157
The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies 153
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 152
A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. 149
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 148
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification? 145
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 145
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 144
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 143
A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. 140
Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. 140
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 138
Clear-cell proliferation of the lung with lymphangioleiomyomatosis-like change 138
Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified 138
Expression of CD52 in peripheral T-cell lymphoma. 136
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 135
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 135
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. 134
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 133
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 133
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma 133
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 133
IFI16 expression is related to selected transcription factors during B-cell differentiation 132
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 131
CD30 expression in peripheral T-cell lymphomas 131
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 131
A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp. 130
Anaplastic Large Cell Lymphoma: a critical reappraisal 128
BCL10 down-regulation in peripheral T-cell lymphomas. 128
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 126
Chronic inflammation, including Autoimmunity, and Lymphomagenesis. 126
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 125
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 125
B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray. 125
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 125
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. 124
B-cells and mixed cryoglobulinemia. 124
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 124
CDK9/Cyclin T1 expression during normal lymphoid differentiation and malignant transformation. 122
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 122
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma 122
Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature 122
Histopathology of B-cell chronic lymphocytic leukemia. 121
Linfomi a cellule T periferiche NAS: nuovo indice prognostico. 121
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma 121
Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma. 121
Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. 119
Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets. 118
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 118
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition 118
Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. 117
Pathobiology of hodgkin lymphoma. 117
Pitfalls in diagnosis: primary mediastinal non-seminomatous germ cell tumour with bone marrow metastasis showing melanoma-like phenotype. 116
A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. 116
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. 115
The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: adipophilin. 115
Rare expression of KIT (CD117) in lymphomas: a tissue microarray study of 1166 cases. 114
A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. 114
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups 114
Aberrant somatic hypermutation in primary mediastinal large B-cell lymphoma. 114
Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas. 114
BCL10 expression in peripheral T-Cell lymphoma not otherwise specified. 113
Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology. 113
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 113
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 112
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 112
Primary effusion lymphoma associated with Human Herpes Virus-8 and Epstein Barr virus in an HIV-infected woman from Kampala, Uganda: a case report. 112
The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. 112
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis 112
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 111
Do bone marrow isolated tumor cells influence long-term survival of non-small cell lung cancer? 111
Molecular genetics of peripheral T-cell lymphomas 111
Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of Follicular dendritic cell sarcomas 111
Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. 110
Aberrant promoter methylation of multiple genes thoughout the clinico-pathologic spectrum of B-cell neoplastia. 110
Histopathological and molecular features of persistent polyclonal B-cell lymphocytosis (PPBL) with progressive splenomegaly. 110
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 110
HIV infection and c-MYC status in endemic Burkitt lymphoma 110
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 110
ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK(+) ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project 110
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 110
Targeted molecular therapy in peripheral T-cell lymphomas 109
Familial haemophagocytic lymphohistiocytosis-related plasma cell neoplasm: a case report. 109
CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? 109
Simple diagnostic assay for hairy cell leukemia by cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). 108
High specificity of combined TRAP and DBA.44 expression for hairy cell leukemia. 108
Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. 108
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 107
Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. 107
Prognostic markers in peripheral T-cell lymphoma. 107
Totale 12.789
Categoria #
all - tutte 77.816
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.816


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.104 0 0 0 0 0 0 0 0 0 417 157 530
2019/202011.366 1.545 281 146 748 1.146 1.190 1.442 1.497 1.525 712 424 710
2020/20215.375 1.159 413 150 231 131 336 59 286 508 286 259 1.557
2021/20226.593 706 232 540 573 677 381 142 449 247 394 1.258 994
2022/20236.393 847 864 353 789 458 472 221 332 1.011 174 504 368
2023/20241.378 89 290 108 174 142 290 109 94 48 34 0 0
Totale 35.031